BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19907075)

  • 1. PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.
    Valenzuela JO; Iclozan C; Hossain MS; Prlic M; Hopewell E; Bronk CC; Wang J; Celis E; Engelman RW; Blazar BR; Bevan MJ; Waller EK; Yu XZ; Beg AA
    J Clin Invest; 2009 Dec; 119(12):3774-86. PubMed ID: 19907075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
    Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
    Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
    Truitt RL; Atasoylu AA
    Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.
    Asakura S; Hashimoto D; Takashima S; Sugiyama H; Maeda Y; Akashi K; Tanimoto M; Teshima T
    J Clin Invest; 2010 Jul; 120(7):2370-8. PubMed ID: 20530875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoting regulation via the inhibition of DNAM-1 after transplantation.
    Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Leveque L; Chan CJ; Robb RJ; Markey KA; Alexander KA; Varelias A; Clouston AD; Smyth MJ; MacDonald KP; Hill GR
    Blood; 2013 Apr; 121(17):3511-20. PubMed ID: 23430112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I-IFNs control GVHD and GVL responses after transplantation.
    Robb RJ; Kreijveld E; Kuns RD; Wilson YA; Olver SD; Don AL; Raffelt NC; De Weerd NA; Lineburg KE; Varelias A; Markey KA; Koyama M; Clouston AD; Hertzog PJ; Macdonald KP; Hill GR
    Blood; 2011 Sep; 118(12):3399-409. PubMed ID: 21719602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.
    Reddy P; Maeda Y; Liu C; Krijanovski OI; Korngold R; Ferrara JL
    Nat Med; 2005 Nov; 11(11):1244-9. PubMed ID: 16227991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
    Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S; Kamisaku H; Sado T
    Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
    Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
    J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.